SL VAXiGEN

2 clinical trials · Sponsor

Record	Firm	Date
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. (NCT06344715)	SL VAXiGEN	2022-10-17
Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient (NCT03576014)	SL VAXiGEN	2018-04-27

Every clearance here is in the API, with alerts when new ones post.